Glonghui November 20: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “When will your long-term whitening and Dagliflogenin plans start selling?” The company replied that the company's long-term libiotic is already on the market, and Daglizine has not yet been produced or marketed.
双鹭药业(002038.SZ)：长效立生素已经上市销售，达格列净目前还没有生产和上市销售
Shuanglu Pharmaceutical (002038.SZ): Long-acting libiotic has been marketed for sale, and Dapagliflozin has not yet been produced or marketed
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.